4233 |
MET PROTO-ONCOGENE, RECEPTOR TYROSINE KINASE |
MET |
AUTS9 |
DFNB97 |
HGFR |
RCCP2 |
c-Met |
164860 |
7029 |
ENSG00000105976 |
OTTHUMG00000023299 |
MET_HUMAN |
P08581 |
HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581] |
HEPATOCYTE GROWTH FACTOR RECEPTOR |
PA30763 |
SF receptor |
HGF receptor |
Tyrosine-protein kinase Met |
Scatter factor receptor |
Proto-oncogene c-Met |
HGF/SF receptor |
52 |
T40474 |
Initial Gene Query | MET |
Counted Citations from 1950-2000 | 4560 |
Human Readable Name | DRUGGABLE GENOME |
Human Readable Name | KINASE |
Interpro Type | Domain |
Uniprot Evidence | 1: Evidence at protein level |
Uniprot Status | Swiss-Prot |
Interpro Acc | IPR001245 |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
CancerCommons Reported Gene Name | MET |
CancerCommons Reported Gene Name | MET, VEGFRs, Axl, Tie2, Ron |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Gene Biotype | PROTEIN_CODING |
CELL SURFACE |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
inhibitor (inhibitory) |
Notes | |
Reported Cancer Type | Lung, Prostate |
Trial Name | ARQ-197 |
antibody (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Indication/Tumor Type | esophagus adenocarcinoma |
Indication/Tumor Type | gastroesophageal junction adenocarcinoma |
Response Type | no benefit |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
Indication/Tumor Type | lung large cell carcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Indication/Tumor Type | prostate cancer |
Response Type | sensitive |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Clinical Status | preclinical |
Pathway | activation |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Phase I |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Indication/Tumor Type | lung cancer |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | stomach cancer |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | stomach cancer |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
inhibitor (inhibitory) |
Notes | |
Reported Cancer Type | Lung |
Trial Name | MGCD265 |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
Trial Name | MP-470 |
inhibitor (inhibitory) |
Approval Status | Preclinical |
combination therapy | Foretinib + Rucaparib |
Evidence Type | Actionable |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Hepatocyte growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
MET | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
MET | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
4233 | Entrez Gene ID |
CancerCommons Reported Gene Name | MET |
CancerCommons Reported Gene Name | MET, VEGFRs, Axl, Tie2, Ron |
4233 | Entrez Gene ID |
Initial Gene Query | MET |
Counted Citations from 1950-2000 | 4560 |
KINASE |
MET_HUMAN | Uniprot Id |
4233 | Entrez Gene Id |
P08581 | Uniprot Accession |
Human Readable Name | KINASE |
Interpro Type | Domain |
Uniprot Evidence | 1: Evidence at protein level |
KINASE, DRUGGABLE GENOME |
ENSG00000105976 | Ensembl Gene Id |
MET | Display Id |
HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
4233 | CKB Entrez Id |
MET | CKB Gene Synonym |
AUTS9 | CKB Gene Synonym |
PA30763 | PharmGKB ID |
4233 | Entrez Gene ID |
52 | CIViC Gene ID |
DRUG RESISTANCE |
MET | Gene Symbol |
HGFR | Gene Symbol |
4233 | Entrez Gene Id |
MET | MyCancerGenome Gene Symbol |
MET | MyCancerGenome Reported Gene Name |
ENSG00000105976 | Gene Symbol |
MET | Ensembl Id |
DRUGGABLE GENOME |
C-MET | Gene Symbol |
MET | GENE_SYMBOL |
Hepatocyte growth factor receptor | UNIPROT |
HGF/SF receptor | UNIPROT |
4233 | OncoKB Entrez Id |
RCCP2 | OncoKB Gene Synonym |
HGFR | OncoKB Gene Synonym |
MET | Gene Symbol |
CLINICALLY ACTIONABLE |
4233 | Gene ID |
AUTS9 | dGene Synonym |
HGFR | dGene Synonym |
KINASE, TYROSINE KINASE |
MET | TTD Gene Abbreviation |
T40474 | TTD Target ID |
Hepatocyte growth factor receptor | Gene Name |
P08581 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CELL SURFACE, TYROSINE KINASE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |